You are here: Industry Insights > RA

News List

Combo Tx May Improve Disease Control for Some in Early RA drugs
August 28, 2019
For patients with early rheumatoid arthritis (RA) and high disease activity, the combination of a tumor necrosis factor (TNF) or non-TNF biologic with methotrexate improves disease control...
Initial Sustained Remission Common in Rheumatoid Arthritis drugs
July 23, 2019
Six-month sustained remission (SR) is not uncommon in patients with rheumatoid arthritis (RA).
Aclaris Therapeutics Submits IND for RA Treatment contractpharma
June 14, 2019
If the IND is allowed by the FDA, Aclaris plans to initiate a Phase 1 trial of ATI-450, an oral MK2 inhibitor in 2H19
Postoperative Infection Rate Similar Across Biologics in RA drugs
May 21, 2019
Postoperative Infection Rate Similar Across Biologics in RA.
Safety Trial Finds Risk of Blood Clots in Lungs and Death with Higher Dose of Tofacitinib in RA Patients; FDA to Investigate americanpharmaceuticalreview
February 27, 2019
The U.S. Food and Drug Administration (FDA) is alerting the public that a safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of tofacitinib ....
AbbVie’s JAK inhibitor upadacitinib gets Priority Review pharmaphorum
February 21, 2019
AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).
Celltrion calls for wider use of biologics in RA pharmatimes
September 14, 2018
Celltrion Healthcare is calling on the NHS to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA), and to put in place...
Could an old Amgen-developed RA drug make CAR-T treatments safer? fiercebiotech
June 11, 2018
The personalized CAR-T cells that are FDA-approved to treat blood cancers, Gilead’s Yescarta and Novartis’s Kymriah, can raise the risk of a side effect that has been challenging to prevent and treat: cytokine release syndrome (CRS).
FDA turns down Janssen's sirukumab for rheumatoid arthritis pharmafile
August 04, 2017
Janssen has announced that it has suffered a knockback to its plans to commercialise sirukumab in the US in the rheumatoid arthritis (RA) space

Previous page 1 2 Next page